HAE — HAEMONETICS CORP
—
NYSE ·
Health Care ·
Health Care Equipment & Supplies ·
CIK 313143 ·
Last close
$120.92
Market Cap
$5.51B
52W High
$132.00
52W Low
$51.00
ADV30
768,944
Next earnings
2027-02-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 357,759,000 | 220,913,000 | 75,120,000 | 46,305,000 | 2,410,605,000 | 260,712,000 | 1,512,108,000 |
| Jun 2026 | 339,380,000 | 202,803,000 | 57,458,000 | 33,010,000 | 2,365,400,000 | 223,384,000 | 1,528,299,000 |
| Mar 2026 | 346,351,000 | 198,212,000 | 52,342,000 | -20,147,000 | 2,395,925,000 | 245,440,000 | 1,599,605,000 |
| Dec 2025 | 338,967,000 | 202,386,000 | 68,112,000 | 44,740,000 | 2,490,890,000 | 363,367,000 | 1,579,439,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$344,928,000
Investing CF
$-162,600,000
Financing CF
$-218,605,000
CapEx
$-46,687,000
Dividends Paid
—
Buybacks
$-250,000,000
EPS Diluted TTM
$2.23
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$356,961,000
Inventory
$305,006,000
Receivables
$224,952,000
ST Investments
—
EBIT TTM
$176,949,000
Pretax Income TTM
$142,009,000
Interest Exp TTM
$34,940,000
Analysts
10
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,382,456,960
EBITDA
$361,214,016
Free Cash Flow
$272,701,248
Enterprise Value
$6,324,362,752
Total Cash
$260,712,000
Total Debt
$1,123,761,024
Shares Out
45,537,511
Trailing EPS
$2.26
Book Value
$19.74
ROE
11.9%
ROA
6.6%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 1,334,027,000 | 241,401,000 | 97,308,000 | 2,395,925,000 | 1,599,605,000 | 796,320,000 | 293,221,000 |
| Mar 2025 | 1,360,824,000 | 201,186,000 | 167,679,000 | 2,450,948,000 | 1,630,112,000 | 820,836,000 | 181,725,000 |
| Mar 2024 | 1,309,055,000 | 175,302,000 | 117,558,000 | 2,195,591,000 | 1,235,632,000 | 959,959,000 | 181,751,000 |
| Mar 2023 | 1,168,660,000 | 155,651,000 | 115,401,000 | 1,934,825,000 | 1,116,828,000 | 817,997,000 | 273,058,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$2,365,400,000
Forward EPS
$5.78
Max Pain — expiry 2028-01-21 (volume-derived — Yahoo OI feed degraded)
max pain strike: $135.00 · spot: $122.86 · call volume: 157 · put volume: 377Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LIVN | LivaNova PLC | $5.06B | $91.92 | — |
| MMSI | MERIT MEDICAL SYSTEMS INC | $5.06B | $84.49 | — |
| MMED | MiniMed Group, Inc. | $5.00B | $17.78 | — |
| TFX | TELEFLEX INC | $6.33B | $159.55 | — |
| MSA | MSA Safety Inc | $6.66B | $172.84 | — |
News headlines (Yahoo Finance, 1h cache)
Haemonetics Announces CE Mark Certification for the VASCADE MVP® XL Venous Vascular Closure System
2026-11-18 11:15 · Yahoo
HAE Q3 CY2026 deep dive: plasma growth and new product launches drive momentum
2026-11-10 12:37 · Yahoo
International Markets and Haemonetics (HAE): A Deep Dive for Investors
2026-11-09 13:15 · Yahoo
Should Raised Revenue Outlook Require Action From Haemonetics Stock Investors?
2026-11-08 02:13 · Yahoo
Haemonetics (HAE) Stock May Be 34% Undervalued On Cash Flow
2026-11-07 15:13 · Yahoo
Haemonetics Q2 Earnings Call Highlights
2026-11-07 14:15 · Yahoo
Haemonetics (HAE) Beats Q2 Expectations, Is The Stock Still Cheap?
2026-11-07 11:09 · Yahoo
Haemonetics Corp (HAE) (Q2 2027) Earnings Call Highlights: Raised Guidance and Expanded CSL ...
2026-11-06 09:12 · Yahoo
Haemonetics Corporation Q2 2027 Earnings Call Summary
2026-11-05 23:43 · Yahoo
Haemonetics (HAE) Q2 2027 Earnings Call Transcript
2026-11-05 20:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.